Regulatory Considerations on Endpoints in Ovarian Cancer Drug Development

Cancer- United States

doi 10.1002/cncr.30652

Full Text

Abstract

Available in

Categories

Cancer Research

Date

May 12, 2017

Authors

Sanjeeve Balasubramaniam

Geoffrey S. Kim

Publisher

Wiley

Related search

Drug Development and Registration: Challenges and Opportunities in Ovarian Cancer

Cancer Research

English

Intracellular Trafficking Considerations in the Development of Natural Ligand-Drug Molecular Conjugates for Cancer

Annals of Biomedical Engineering

Biomedical Engineering

English

Drug Combo May Be Effective in Ovarian Cancer

Cancer Discovery

English

Role of Model‐Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling

Journal of Clinical Pharmacology

English

Pharmacodynamic Endpoints as Clinical Trial Objectives to Answer Important Questions in Oncology Drug Development

Seminars in Oncology

English

Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations

Basic and Clinical Pharmacology and Toxicology

English

Diagnostics in Cancer Drug Development

Expert Review of Molecular Diagnostics

Forensic Medicine

Molecular Medicine

Molecular Biology

Dutch

Nano Drug Delivery Systems for Ovarian Cancer Therapy

Integrative Cancer Science and Therapeutics

English

Molecular Imaging in Cancer Drug Development

Journal of Nuclear Medicine

Nuclear Medicine

Dutch